Complete financial analysis of United Health Products, Inc. (UEEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of United Health Products, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Yuh Shan (7715.TWO) Income Statement Analysis – Financial Results
- SNT Motiv Co., Ltd. (064960.KS) Income Statement Analysis – Financial Results
- Public Joint Stock Company Varyoganneftegaz (VJGZ.ME) Income Statement Analysis – Financial Results
- FLSmidth & Co. A/S (FLIDF) Income Statement Analysis – Financial Results
- Cosmo Advanced Materials & Technology Co., Ltd. (005070.KS) Income Statement Analysis – Financial Results
United Health Products, Inc. (UEEC)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
About United Health Products, Inc.
United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers HemoStyp hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, assisted living and nursing homes, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. United Health Products, Inc. was incorporated in 1997 and is headquartered in Henderson, Nevada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 37.50K | 59.00 | 643.00 | 4.93K | 45.86K | 645.65K | 242.01K | 53.27K | 162.68K | 3.06K | 0.00 | 0.00 | 69.07K | 23.90K | 8.19K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.86K | 18.64K | 25.00 | 195.00 | 1.32K | 96.70K | 67.02K | 117.93K | 27.51K | 82.96K | 0.00 | 0.00 | 0.00 | 56.45K | 16.64K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.86K | 18.86K | 34.00 | 448.00 | 3.61K | -50.84K | 578.64K | 124.08K | 25.75K | 79.71K | 3.06K | 0.00 | 0.00 | 12.62K | 7.26K | 8.19K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 50.28% | 57.63% | 69.67% | 73.29% | -110.85% | 89.62% | 51.27% | 48.35% | 49.00% | 100.00% | 0.00% | 0.00% | 18.28% | 30.38% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 598.81K | 624.56K | 237.46K | 245.22K | 666.39K | 76.95K | 19.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.22M | 107.02K | 0.00 | 0.00 | 487.06K | 284.88K | 228.27K | 191.16K | 15.50K |
| Selling & Marketing | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.82M | 2.20M | 29.56M | 14.60M | 5.43M | 2.25M | 1.30M | 641.55K | 2.61M | 2.12M | 1.22M | 107.02K | 1.22M | 2.55M | 487.06K | 284.88K | 228.27K | 191.16K | 15.50K |
| Other Expenses | 0.00 | 1.40M | 304.27K | 0.00 | 0.00 | 3.94K | 0.00 | 0.00 | 0.00 | 50.00K | 259.04K | 100.00K | 100.00K | 100.00K | 50.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.43M | 2.82M | 29.80M | 14.85M | 6.10M | 2.33M | 1.30M | 641.55K | 2.61M | 2.17M | 1.32M | 207.02K | 1.32M | 2.65M | 537.06K | 284.88K | 228.27K | 191.16K | 15.50K |
| Cost & Expenses | 2.43M | 2.84M | 29.80M | 14.85M | 6.10M | 2.42M | 1.36M | 759.48K | 2.64M | 2.25M | 1.32M | 207.02K | 1.32M | 2.70M | 553.70K | 284.88K | 228.27K | 191.16K | 15.50K |
| Interest Income | 0.00 | 78.85K | 618.25K | 546.23K | 508.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 78.85K | 618.25K | 546.23K | 508.18K | 0.00 | 39.48K | 18.26K | 9.15K | 52.15K | 68.70K | 0.00 | -270.95K | 81.13K | 81.30K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.05K | 4.05K | 29.80M | 14.85M | 6.09M | 1.90M | 1.01M | 517.48K | 50.00K | 50.00K | 100.00K | 100.00K | 100.00K | 100.00K | 50.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -2.50M | -1.60M | -748.55K | -862.75K | -6.09M | -5.40M | -534.67K | -517.48K | -2.58M | -2.04M | -1.22M | -107.02K | -1.22M | -2.53M | -796.32K | -276.69K | -228.27K | -191.16K | -15.50K |
| EBITDA Ratio | 0.00% | -3,720.02% | -49,993,833.90% | -2,309,276.98% | -123,688.09% | -5,175.60% | -82.81% | -213.83% | -4,848.71% | -1,255.36% | -39,761.67% | 0.00% | 0.00% | -3,929.97% | -3,171.08% | -3,378.38% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.43M | -2.80M | -29.80M | -14.85M | -6.09M | -2.38M | -719.32K | -517.48K | -2.58M | -2.09M | -1.32M | -207.02K | -1.32M | -2.63M | -529.79K | -276.69K | -228.27K | -191.16K | -15.50K |
| Operating Income Ratio | 0.00% | -7,472.10% | -50,509,550.85% | -2,309,276.98% | -123,688.09% | -5,184.18% | -111.41% | -213.83% | -4,848.71% | -1,286.10% | -43,029.64% | 0.00% | 0.00% | -3,814.15% | -2,216.43% | -3,378.38% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -196.73K | 1.11M | -748.55K | -862.75K | -508.18K | -3.51M | -215.65K | -18.26K | -9.15K | -52.15K | 190.34K | -74.40K | -270.95K | -261.13K | -380.21K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -2.62M | -1.69M | -30.55M | -15.71M | -6.60M | -6.01M | -934.97K | -535.74K | -2.59M | -2.14M | -1.13M | -281.41K | -1.59M | -2.90M | -910.01K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | -4,500.00% | -51,778,276.27% | -2,443,452.57% | -134,002.33% | -13,096.10% | -144.81% | -221.37% | -4,865.88% | -1,318.15% | -36,809.35% | 0.00% | 0.00% | -4,192.21% | -3,807.08% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.11K | 618.25K | 546.23K | 508.18K | 3.63M | 31.00K | -517.48K | -50.00K | 0.00 | 68.70K | 0.00 | 0.00 | -98.87K | -196.89K | 276.69K | 228.27K | 191.16K | 15.50K |
| Net Income | -2.62M | -1.69M | -31.17M | -16.26M | -7.11M | -6.01M | -934.97K | -535.74K | -2.59M | -2.14M | -1.13M | -281.41K | -1.59M | -2.90M | -910.01K | -276.69K | -228.27K | -191.16K | -15.50K |
| Net Income Ratio | 0.00% | -4,497.03% | -52,826,159.32% | -2,528,402.49% | -144,316.58% | -13,096.10% | -144.81% | -221.37% | -4,865.88% | -1,318.15% | -36,809.35% | 0.00% | 0.00% | -4,192.21% | -3,807.08% | -3,378.38% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | -0.14 | -0.09 | -0.04 | -0.03 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | 0.00 | -0.02 | -0.06 | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.14 | -0.09 | -0.04 | -0.03 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | 0.00 | -0.02 | -0.06 | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 239.09M | 229.72M | 225.74M | 183.76M | 175.88M | 172.12M | 155.83M | 152.10M | 138.68M | 102.95M | 94.40M | 83.37M | 80.85M | 50.96M | 39.36M | 33.66M | 28.78M | 28.62M | 52.09M |
| Weighted Avg Shares Out (Dil) | 239.08M | 229.72M | 225.74M | 183.76M | 175.88M | 172.12M | 155.83M | 152.10M | 138.68M | 102.95M | 94.40M | 83.37M | 80.85M | 50.96M | 39.36M | 33.66M | 41.78M | 41.73M | 52.09M |
United Health Products Provides Corporate Update and Announces Equity Financing
United Health Products' HemoStyp® Gauze Advances to FDA Substantive Review
Source: https://incomestatements.info
Category: Stock Reports